Fusion Pharmaceuticals Inc.: federal grants and contributions: 5 agreements; $1.7M value; 1 departments; 3 programs.
Assay record ASY-CA-0JX6S2N16J · Cite as: Assay Systems, “Fusion Pharmaceuticals Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/fusion-pharmaceuticals-inc/
This project is focused on the discovery and pre-clinical development of targeted alpha therapeutics using camelid-based constructs for the treatment of solid tumors with high unmet medical need.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
Fusion Pharmaceuticals, Inc. is a new Canadian pharmaceutical company that develops innovative targeted radiotherapy drugs. The project is focused on studying the synergistic effects of Fusion’s targeted radiotherapies with immunotherapies to create new cancer treatment strategies and expand investment and commercialization opportunities for Fusion.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.